

## Symposium 1: Measurement of sensitive behaviour

### S1.1 IMPROVING THE VALIDITY OF SEXUAL BEHAVIOUR MEASUREMENT: USING COMPUTER-ASSISTED METHODS

doi:10.1136/sextrans-2011-050102.1

<sup>1,2</sup>F M Cowan. <sup>1</sup>University College London, London, UK; <sup>2</sup>College of Health Sciences, University of Zimbabwe, Zimbabwe

Reporting of sexual behaviour is subject to bias, perhaps most importantly social desirability bias. This is a particular problem in communities where discussion of sex is considered taboo and when disclosure of sexual activity can have serious consequences for the individuals concerned (eg, for young people or those in same-sex relationships). Mis/under-reporting of sexual behaviours can result in the design of interventions being poorly informed as well as in intervention effectiveness being unreliably measured. There is increasing evidence to suggest that questionnaire delivery method (in addition to a host of other factors) can impact the validity of reported data and that validity can be improved by careful consideration of questionnaire delivery mode. Computer-assisted questionnaire delivery has been shown to increase reporting of socially sanctioned behaviours in many settings and even in rural, resource poor settings, where people traditionally have limited experience of using computers, have been shown to be highly acceptable and feasible to research participants.

### S1.2 APPLYING SEMEN BIOMARKERS TO HIV/STI RESEARCH

doi:10.1136/sextrans-2011-050102.2

M F Gallo. National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Research on the prevention of HIV/STIs generally has relied on self reports of sexual activity, which are vulnerable to bias. Self-reported data on sexual behaviours could have poor validity for several reasons, namely social desirability bias, recall bias, lack of awareness of exposure (eg, undetected condom breakage), and poor comprehension or misinterpretations of the survey questions. This presentation will briefly describe biomarkers of semen exposure, in particular, prostate-specific antigen detected in vaginal fluid, and will give examples of the ways in which biomarkers could be used to strengthen research on (1) effectiveness of barrier methods against HIV/STIs; (2) effectiveness of behavioural interventions to prevent HIV/STIs; (3) condom "migration" from HIV/STI interventions; (4) the validity of self-reported data; and (5) methods to improve the validity of self-reported data. Limitations of biomarkers include their narrow scope, cost, relatively quick clearance, and unknown biological significance of biomarker levels in relation to risk of HIV/STIs. Finally, examples of future areas of research will be provided.

### S1.3 MEASUREMENT OF ADHERENCE: WHERE ARE WE?

doi:10.1136/sextrans-2011-050102.3

A Van der Straten. University of California, San Francisco, California, USA

There is presently no validated objective method available to measure participants' sexual behaviour or adherence to study product use in HIV prevention trials. Because of this challenge there has been an indeterminate amount of product non-adherence that has precluded the accurate measurement of the safety and efficacy of novel biomedical interventions. Measurement has historically relied on self-report, which suffers from several biases, including recall and social desirability. To address these, researchers have used alternative interview modes (ACASI) and technologies (cell phones/SMS) with

varying success. Pros and cons of other innovative approaches to measure adherence will be discussed, including use of indirect objective measures of adherence (eg, events monitoring systems, mucin tests of gel applicators), real time electronic measures, biomarkers and Directly Monitored Adherence Methods. Each of these approaches has strengths and limitations, thereby precluding any of them from serving as a universal "gold standard". Discussion will include what can and should be measured "objectively" as well as lessons learnt for future biomedical prevention trials.

### S1.4 PHARMACOLOGICAL ASSESSMENT OF MEDICATION ADHERENCE—ORAL PREP AND MICROBICIDES

doi:10.1136/sextrans-2011-050102.4

C Hendrix. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

HIV chemoprevention trials (oral PrEP and topical microbicides) will benefit greatly from an accurate assessment of medication adherence during the trial to assist in the interpretation of prevention success or failure in the trial. HIV infection during the trial may be a result of failure to achieve preventive drug concentrations, which itself may result from either (1) a prescribed regimen, to which the subject fully adhered, that is still insufficient to prevent infection or (2) a result of poor adherence to the prescribed regimen also resulting in insufficient drug concentrations. In addition, an accurate adherence assessment in the midst of a trial could trigger adherence interventions. Objective evidence of adherence in several HIV chemoprevention trials suggests that subjective measures greatly overestimate adherence. Drug concentration has been proposed as a more objective adherence measure. Blood, hair, or other samples are sampled at specified times and the resultant "observed" drug concentration is compared to the "expected" drug concentration. The proportional difference between the expected and observed drug concentrations may be used as an estimate of the proportion of doses for which the subject was adherent to the prescribed regimen. This method attempts to provide more accurate and quantitative measures than those currently employed, but obstacles to their application and feasibility in estimating adherence remain to be demonstrated. Problems of white-coat effect, inter- and intra-individual variability, dose-proportionality, and backward looking temporal frame of reference all need to be addressed as part of the validation and interpretation of drug concentration as an adherence measure.

## Symposium 2: Rapid tests as tools to transform policy, strengthen health systems and save lives (sponsored by WHO/TDR and the London school of hygiene and tropical medicine)

### S2.1 INTRODUCTION OF RAPID SYPHILIS TESTS IN ANTENATAL CARE SERVICES IN TANZANIA: CLIENTS' AND SERVICE PROVIDERS' ACCEPTABILITY AND UPTAKE OF TESTING

doi:10.1136/sextrans-2011-050102.5

<sup>1</sup>J Changalucha, <sup>1</sup>J Moshia, <sup>1</sup>J Mngara, <sup>2</sup>C Masesa, <sup>3</sup>L Kabalila, <sup>3</sup>E Makaranga, <sup>3</sup>K Sollis, <sup>3</sup>S Kapiga, <sup>4</sup>D Mabey, <sup>4</sup>R Peeling. <sup>1</sup>National Institute for Medical Research, Mwanza, Tanzania; <sup>2</sup>Mwanza Intervention Trials Unit, Tanzania; <sup>3</sup>Harvard School of Public Health, Boston, USA; <sup>4</sup>London School of Health and Tropical Medicine, London, UK

**Background** Syphilis is still a major cause of morbidity and mortality in women and children. In Tanzania syphilis was shown to cause adverse pregnancy outcomes in 49% and stillbirth in 25% of